Labiotech.eu

News and Trends 10 Jul 2015

First-in-human successful Phase I for an Alzheimer’s vaccine

AXON Neuroscience has completed a pioneer Phase I that offers new hope for millions of patients with Alzheimer’s disease. This makes AXON the first company to successfully complete this clinical trial for a vaccine that targets diseased tau proteins, which cause neural degeneration. Alzheimer’s disease is characterized by the presence of prejudicial forms of protein […]

July 10, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Jul 2015

Sanofi to solve Growing Resistance against Malarial Treatments

Sanofi extended its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new combination therapy against malaria, the deadliest parasitic disease worldwide. The difficult access and the fear of a growing resistance to the existing treatments highlight the importance of this partnership. Atemisinin-based combination therapies (ACT) are at this moment the most efficient […]

July 10, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 10 Jul 2015

Greenovation: Using Moss as a Drug Production Factory

Factor H, a key component of the immune system that is missing in patients suffering from atypical hemolytic uremic syndrome (aHUS) was effectively produced in the moss Physcomitrella patens. In collaboration with the University of Freiburg, Greenovation now aims to humanize the protein to suit it for clinical use. The complement system is part of […]

July 10, 2015 - 2 minutesmins - By Philip Hemme

eye Bayer Healthcare Johns Hopkins University

News and Trends 9 Jul 2015

Vision specialist Gensight eyes a €90M IPO on NASDAQ

French Gensight intends to raise one of the biggest European IPOs on the American stock market. The gene-therapy specialist will pursue €90.6M to advance with two early-stage candidates for orphan eyes diseases. Gensight will travel across the Ocean to look for the same success its compatriots had on the American stock market. The company will […]

July 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 9 Jul 2015

Oasmia anticipates an Oncology market growth and seeks €23M on NASDAQ

Human and veterinary oncologist Oasmia files for a €23M IPO on the American NASDAQ. The Swedish company, anticipating an increase in the oncology field, seeks to increase its visibility and to establish itself in the US. The papers have been sent, Oasmia Pharmaceutical will go to NASDAQ under the symbol OAX. The Swedish company was […]

July 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 9 Jul 2015

Meet Eligo, the Startup which Raised €2M to Redefine Antibiotics using CRISPR

Antibiotic resistance is a public health problem worldwide. According to WHO, by 2050, over 10 million people will die every year. Microbiomics is a fast evolving field which could play an important role in fighting these resistant bacteria. And CRISPR is literally seen as the biggest Biotech discovery of this century. So, here’s a crazy thought… what would […]

July 9, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 8 Jul 2015

First Success for Imperial Innovations’ Gene Therapy in Cystic Fibrosis

Good news for patients suffering from cystic fibrosis! Imperial Innovations‘ patented gene therapy could improve the patients’ breathing provoking any side effects. An innovation that could help fulfill this unmet medical need. Cystic fibrosis is the most common deadly genetic disease in Europe. Gene deficiency leads to thickening mucus that obstructs lungs and results in […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 Jul 2015

Genmab and Novartis look for the European approval of their leukemia candidate

Genmab is seeking the European authorization for Arzerra, a treatment co-developed with Novartis. The submission is based on the candidate’s positive results in its Phase III in patients with leukemia. Arzerra, the commercial name for ofatumumab, is a human monoclonal antibody that directs the body’s immune system to fight normal and cancerous B-lymphocytes. The drug […]

July 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Jul 2015

CureVac’s mRNA Therapy is Working Against Prostate Cancer

mRNA based immunotherapies are no pipe dream anymore. Germany’s CureVac just presented encouraging results of its Phase IIa clinical study. The firm’s lead mRNA candidate CV9103 is well tolerated and immunogenic in patients with prostate cancer. Based on the favorable data, CureVac initiated a Phase IIb study with a follower prostate cancer vaccine. Just recently, […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Jul 2015

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

Novo Nordisk cancels its collaboration deal with Zosano Pharma. The diabetes drug semaglutine won’t be delivered with the microneedle patch technology, developed from the latter. Zosano’s patch technology uses thin titanium microprojections to deliver drugs that cannot permeate the outer layer of the skin. According to Zosano, the system was tested on 400 patients in […]

July 7, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Jul 2015

DIY-Morphine is around the corner with recent Discoveries in Poppies

Bioproduction of future painkillers such as morphine could become a reality. Researchers from the University of York and GlaxoSmithKline Australia made crucial genetic discoveries in the morphinan synthesis pathway, which will allow its production in microbial systems or in genetically selected plant breeds. Opioid alkaloids have been used as painkillers since the dawn of time. The opium latex is […]

July 7, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 Jul 2015

Microalgae on Your Plate Thanks to Algama

Nine billion people will have to be fed by 2050! Amongst the considered solutions, microalgae could be a real game-changer. Algama, a young French startup is in the starting-block, with already two products just about to go on the market. Behind Algama there is a friendship story, shared by the three co-founders, Alvyn, Gaëtan and Mathieu. […]

July 7, 2015 - 4 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

First-in-human successful Phase I for an Alzheimer’s vaccine

Sanofi to solve Growing Resistance against Malarial Treatments

Greenovation: Using Moss as a Drug Production Factory

Vision specialist Gensight eyes a €90M IPO on NASDAQ

Oasmia anticipates an Oncology market growth and seeks €23M on NASDAQ

Meet Eligo, the Startup which Raised €2M to Redefine Antibiotics using CRISPR

First Success for Imperial Innovations’ Gene Therapy in Cystic Fibrosis

Genmab and Novartis look for the European approval of their leukemia candidate

CureVac’s mRNA Therapy is Working Against Prostate Cancer

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

DIY-Morphine is around the corner with recent Discoveries in Poppies

Microalgae on Your Plate Thanks to Algama

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!